Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2014Clinical EpidemiologyOpen Access

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPuey Ling ChiaTJThomas JohnADAlexander Dobrovic

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chia et al. (2014) studied this question.

synapsesocial.com/papers/6a778315df493903fd1efdfehttps://doi.org/10.2147/clep.s69718
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A mouse model for <i>EML4-ALK</i> -positive lung cancer2008 · 512 citations
  2. 2First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.2014 · 104 citations
  3. 3Multiplex Reverse Transcription-PCR Screening for <i>EML4-ALK</i> Fusion Transcripts2008 · 507 citations
  4. 4Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib2006 · 591 citations
  5. 5Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)2000 · 225 citations